Loading clinical trials...
Loading clinical trials...
A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome
Conditions
Interventions
NT-501
NT-501
Locations
12
United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
University of Califoria, Davis
Sacramento, California, United States
University of California, San Francisco
San Francisco, California, United States
Bascom Palmer Eye Insitute
Miami, Florida, United States
Kellogg Eye Center
Ann Arbor, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Start Date
January 22, 2007
Primary Completion Date
April 19, 2010
Completion Date
April 19, 2010
Last Updated
May 1, 2025
NCT07548944
NCT05926583
NCT07174726
NCT07292987
NCT06789445
NCT04639635
Lead Sponsor
Neurotech Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions